Cystic Fibrosis Therapeutics Market

The global cystic fibrosis therapeutics market size was USD 11.46 billion in 2022, and it is anticipated to expand at USD 43.92 billion in 2031, at a CAGR of 16.1% during the forecast period 2023-2031. One of the other key factors expected to boost the growth of the market is an increase in the rate of treatment for cystic fibrosis.

Moreover, the favorable government regulations to support the development of advanced drugs for the treatment are anticipated to help the market growth. Cystic fibrosis is a rare and serious life-threatening disease that is genetic in nature caused by the alteration of cystic fibrosis transmembrane conductance regulator (CFTR).

Get Free Sample Report

The genetic disorder can cause damage to the digestive system and lungs as well as affect cells that produce digestive juices sweat and mucus gets sticky and thick. The data published by the Cystic Fibrosis Foundation states that such genetic disorders are increasing continuously. The number of patients increased from 26,366 in 2010 to 28,983 in 2015.

Due to the increase in the number of patients, there is increasing demand for cystic fibrosis that is effective and efficient. Pancreatic enzyme supplements, bronchodilators drugs, anti-inflammatory drugs, mucolytic drugs, anti-infective, antibiotics (oral, inhaled, or parental feeding formulae), and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are some of the approved drugs that are commercially available.

In order to broaden the base target patient with the present drug portfolio, several clinical trials are being conducted at a regular basis. AZD-5634; PTI-428; QR-010; POL-6014; and VX-445 + tezacaftor + ivacaftor are some of the main pipelined drugs for the treatment of the disorder. Various activities associated with Cystic fibrosis are performed by non-profit organizations including Cystic Fibrosis Worldwide, Cystic Fibrosis Foundation, South African Cystic Fibrosis Association, South African Cystic Fibrosis Trust, and Cystic Fibrosis Canada.

Market Trends, Drivers, Restraints, and Opportunities

• Rise in funding for research and development by both public and private organizations is anticipated to boost the growth of the market.

• Increase in the number of healthcare initiatives taken by both the government and non-profit organizations in order to raise awareness of the disorder among people is one of the key driving factors of the market.

• Availability of favorable reimbursement policies and rapid development of new drugs for the treatment are another major factors helping the market growth.

• Potential candidates for the clinical pipeline are increasing and rising approval of the drugs are some key driving factors of the market.

• High cost of the treatment of this disease is proved to be a restraining factor and is expected to hinder the growth of the market.

Scope of the Cystic Fibrosis Therapeutics Market Report

The report on the global cystic fibrosis therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also
been included in the report.

Cystic Fibrosis Therapeutics Market Segment Insights

Modulators segment is anticipated to expand at a high growth rate

Based on drug classes, the global cystic fibrosis therapeutics market is categorized as bronchodilators, CFTR modulators, pancreatic enzyme supplements, and mucolytics. In the treatment of cystic fibrosis, the chief contemplation is the management of nutritional therapy, controlling respiratory infection while maintaining the functioning of the lungs, and controlling complications.

The first CFTR modulator drug was launched in 2014 named Kalydeco and was the only drug till 2014. The CFTR modulators segment dominated the market with the major revenue share of the market in 2019 and is anticipated to expand at a high growth rate during the projected period owing to the launch of new drugs including Orkambi. This drug enables the correcting of the defective function of the protein.

Get Free Sample Report

Oral drugs segment is expected to grow at a significant pace

Based on the routes of administration, the market is bifurcated into inhaled drugs and oral drugs. The oral drugs segment held a major share of the market in 2019 and is expected to grow at a significant pace in the targeted years attributed to ease of use without the help of any professional. The growth of the market is also dependant on the increasing awareness regarding the benefits of oral drugs.

Pancreatic enzyme supplements including Viokace, Creon/Zenpep, Ultresa, and PERTZYE and CFTR modulators including ORKAMBI and KALYDECO are some of the therapeutics that are approved.

These drugs are high in demand and are commercially available on a huge basis, which is expected to boost the growth of the market segment. A rise in the number of clinical trials is another key factor that helps the segment growth along with an increase in investments made by the public and private organizations.

Asia Pacific market is anticipated to register a healthy CAGR

In terms of regions, the global cystic fibrosis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to hold a large share of the market in the coming years due to a high number of people being affected with cystic fibrosis and several initiatives taken by Cystic Fibrosis Canada and Cystic Fibrosis Foundation.

On the other hand, the Asia Pacific market is anticipated to register a healthy CAGR during the forecast period attributed to increase in awareness regarding cystic fibrosis and wide availability of the treatment options. Moreover, the development of the economy and an increase in the development of healthcare facilities present another key drivers of the regional market growth.

Get Free Sample Report

Segments

The global cystic fibrosis therapeutics market has been segmented on the basis of

Drug Classes

• Bronchodilators
• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics

Routes of Administration

• Inhaled Drugs
• Oral Drugs

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• AstraZeneca
• AbbVie
• IncGilead
• Novartis AG
• Alaxia
• Vertex Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• AIT (Advanced Inhalation Therapies)
• Alcresta Therapeutics, Inc.
• Allergan
• F. Hoffmann-La Roche Ltd.

Competitive Landscape

Key players competing in the global cystic fibrosis therapeutics market are AstraZeneca; AbbVie, IncGilead; Novartis AG; Alaxia; Vertex Pharmaceuticals Inc,; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; AIT (Advanced Inhalation Therapies); Alcresta Therapeutics, Inc.; Allergan; and F. Hoffmann-La Roche Ltd.

Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.